William R Jellison bought $463k of MDT
director at Medtronic plc. 5,000 shares at an average of $92.55, traded Aug 22, 2025, filed Aug 25, 2025.
Score components
- +15RoleDirector
- +17Trade size$463k at market
- +8Relative to holdingsFirst purchase: no shares before this trade
- 0Price contextNear the top of the 52-week range
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001613103-25-000157, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 22, 2025 | POpen-market purchase Ordinary Shares | +2,500 | $92.73 | $232k | 2,500 | Aug 25, 2025 |
| Aug 25, 2025 | POpen-market purchase Ordinary Shares | +2,500 | $92.37 | $231k | 5,000 | Aug 25, 2025 |
Related signals
Other insiders at Medtronic plc and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 26Weak | MDTsell Medtronic plc | Harry Skip Kiil EVP & President Cardiovascular | $139k 1,483 shares | -3% | |
| 42Moderate | MDTsell Medtronic plc | Harry Skip Kiil EVP & President Cardiovascular | $788k 8,605 shares | -19% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.